Wehmeier PM et al. – This secondary analysis provided evidence that atomoxetine (ATX) reduced ADHD symptom severity measured by computer–based Continuous Performance Test (cb–CPT)/motion tracking (MT) parameters regardless of stimulant pretreatment. A few differential effects were seen based on the cb–CPT/MT. However, no clear pattern could be identified and, overall, the observed differences have no larger clinical relevance. The ATX effect in this study seemed to be largely independent of any previous exposure to stimulants.

• Double–blind, placebo–controlled study in ADHD patients (6–12 years) treated with ATX (target dose = 1.2 mg/kg per day).
• The cb–CPT/MT scores were analyzed using ANCOVA (last observation carried forward).

• Patient data (n = 125) suggested a differential ATX treatment effect between pretreated and stimulant–naive patients in terms of three cb–CPT/MT parameters.